What question did this study set out to answer?

To evaluate the safety, feasibility, and efficacy of sequential treatment with two distinct BCMA-directed CAR T-cell products in patients with relapsed or refractory multiple myeloma.

July 11, 2025Blood AdvancesOpen Access

Sequential BCMA CAR T-cell therapy in refractory multiple myeloma

View Full Paper

Ask AI

Bookmark

Authors

TRTim Richardson UHUdo Holtick JFJan Frenking

Discussion

Member takes

Overview

Multicenter cohort study demonstrates high response rates to sequential BCMA CAR T-cell therapy in relapsed multiple myeloma, indicating the feasibility of retargeting the same antigen.

Key Points

To evaluate the safety, feasibility, and efficacy of sequential treatment with two distinct BCMA-directed CAR T-cell products in patients with relapsed or refractory multiple myeloma.
Conducted a real-world multicenter study of N=10 heavily pretreated patients with relapsed or refractory multiple myeloma across 3 medical centers.
Administered ciltacabtagene autoleucel upon relapse following prior treatment with idecabtagene vicleucel, permitting bridging therapies between infusions.
Second CAR T-cell infusion achieved a 100% response rate of at least very good partial response and a 60% minimal residual disease negativity rate.
Estimated 6-month progression-free survival following the second infusion was 64.8% (95% CI, 39%-100%), with duration of response to initial CAR T-cell therapy predicting second-line durability.
Treatment demonstrated an acceptable safety profile without high-grade immune-mediated toxicities, though 1 of 3 relapsed patients exhibited BCMA antigen loss.

Cite This Study

Richardson et al. (2025) studied this question.

synapsesocial.com/papers/6a7d00c4f1daba58ecd59d04 https://doi.org/10.1182/bloodadvances.2025016712

View Full Paper

Ask AI

Bookmark

July 11, 2025Blood AdvancesOpen Access

Sequential BCMA CAR T-cell therapy in refractory multiple myeloma

View Full Paper

Ask AI

Bookmark

Authors

TRTim Richardson UHUdo Holtick JFJan Frenking

Discussion

Member takes

Overview

Multicenter cohort study demonstrates high response rates to sequential BCMA CAR T-cell therapy in relapsed multiple myeloma, indicating the feasibility of retargeting the same antigen.

Key Points

To evaluate the safety, feasibility, and efficacy of sequential treatment with two distinct BCMA-directed CAR T-cell products in patients with relapsed or refractory multiple myeloma.
Conducted a real-world multicenter study of N=10 heavily pretreated patients with relapsed or refractory multiple myeloma across 3 medical centers.
Administered ciltacabtagene autoleucel upon relapse following prior treatment with idecabtagene vicleucel, permitting bridging therapies between infusions.
Second CAR T-cell infusion achieved a 100% response rate of at least very good partial response and a 60% minimal residual disease negativity rate.
Estimated 6-month progression-free survival following the second infusion was 64.8% (95% CI, 39%-100%), with duration of response to initial CAR T-cell therapy predicting second-line durability.
Treatment demonstrated an acceptable safety profile without high-grade immune-mediated toxicities, though 1 of 3 relapsed patients exhibited BCMA antigen loss.

Cite This Study

Richardson et al. (2025) studied this question.

synapsesocial.com/papers/6a7d00c4f1daba58ecd59d04 https://doi.org/10.1182/bloodadvances.2025016712

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark